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Abstract Intercellular communication plays an important
role in cancer initiation and progression through secretory
molecules, including growth factors and cytokines. Recent
advances have revealed that small membrane vesicles,
termed extracellular vesicles (EVs), served as a regulatory
agent in the intercellular communication of cancer. EVs
enable the transfer of functional molecules, including
proteins, mRNA and microRNAs (miRNAs), into recipient
cells. Cancer cells utilize EVs to dictate the unique phe-
notype of surrounding cells, thereby promoting cancer
progression. Against such ‘‘education’’ by cancer cells,
non-tumoral cells suppress cancer initiation and progres-
sion via EVs. Therefore, researchers consider EVs to be
important cues to clarify the molecular mechanisms of
cancer biology. Understanding the functions of EVs in
cancer progression is an important aspect of cancer biology
that has not been previously elucidated. In this review, we
summarize experimental data that indicate the pivotal roles
of EVs in cancer progression.
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Introduction
The malignant phenotypes of tumors not only are determined
by cancer cells themselves but also depend on their sur-
rounding tumor microenvironments [1, 2]. These
microenvironments consist of various cell types, such as
fibroblasts, lymphocyte, inflammatory cells, epithelial cells,
endothelial cells, and mesenchymal stem cells. These cells
within the tumor microenvironment and cancer cells interact
with each other and form the intrinsic communication net-
works that affect several cancer hallmarks, as described by
Hanahan and Weinberg [3]. Several reports documented that
such intercellular communications were modulated by var-
ious humoral factors, such as growth factors, cytokines, and
chemokines. Similar to these molecules, recent advances in
cancer biology revealed that extracellular vesicles (EVs)
also served as a regulatory agent in such communications.
EVs have a heterogenetic population and are generally
categorized as exosome, microvesicles or ectosomes, and
apoptotic bodies [4–6]. These vesicles originate from dif-
ferent subcellular compartments [4–6]. Exosomes are small
membrane vesicles, ranging from 50 to 150 nm in diame-
ter, that have a lipid bilayer membrane and originate from
the exocytosis of multivesicular bodies (MVBs) containing
intraluminal vesicles [6]. Exosome biogenesis and release
are modulated by the endosomal sorting complex that is
required for transport (ESCRT) machinery and the cer-
amide-dependent pathway [6]. Researchers in EV biology
have identified several types of exosome markers, includ-
ing tetraspanins (CD9, CD63, CD81), heat shock proteins
(HSP60, 70, and 90), membrane transporters and fusion
proteins (Annexins and flotillin), and MVB synthesis pro-
teins (Alix and TSG101) [7]. Microvesicles are
100–1000 nm in diameter and are produced directly from
the plasma membrane via budding [8]. Microvesicles are
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enriched in some lipid components and phosphatidylserine
[9]. The biogenesis of microvesicles is modulated by the
interaction between phospholipid redistribution and the
contraction of cytoskeletal structures [10]. Apoptotic bod-
ies (500–4000 nm in diameter) are formed during the
apoptotic process and contain organelles and nuclear
fragments [6, 10, 11]. Apoptotic bodies also contain DNA
fragments and RNA. Macrophages subsequently clear
apoptotic bodies by phagocytosis [11]. However, these
apoptotic bodies may participate in the intercellular com-
munication of the cancer microenvironment. Indeed,
H-rasV12- and human c-myc-transfected to rat fibroblasts
could transfer their DNA to other fibroblasts by apoptotic
bodies, thereby inducing tumorigenic phenotypes [12].
EVs contain functional cellular components such as pro-
teins, mRNAs, and microRNAs (miRNAs) that enable the
transfer of these principal factors to various cell types [13].
These components of EVs are also functional in the recipient
cells and are highly variable depending on the origin cells
[6]. As shown in Figs. 1 and 2, this EV-mediated interaction
between cancer cells and their surrounding cells within
tumor microenvironment confers advantages for cancer
initiation and progression. Non-tumoral cells also utilize
EVs to transfer the tumor-suppressive molecules that affect
cancer initiation and progression (Fig. 2). Therefore,
researchers consider EVs to be important cues for under-
standing the molecular mechanisms underlying the
intercellular communication in the tumor microenviron-
ment. In this review, we will summarize the current
knowledge regarding the functional role of EV components
on intercellular communication between cancer cells and
each cell type within the tumor microenvironment.
Interaction between cancer cells and surrounding
stromal fibroblasts via EVs
The fibroblasts within tumor stroma, which are also termed
cancer-associated fibroblasts (CaFs), have heterogeneous
populations and include myofibroblasts that are similar to
fibroblasts associated with wound healing [14]. CaFs
enable the formation of a unique microenvironment that
plays a pivotal role in cancer development and progression.
Although the origins of CaFs and the signaling that
mediates CaF induction remain controversial, several types
of factors, including transforming growth factor-beta
(TGF-b), are required for the induction and maintenance of
CaFs [14–18]. In addition to these factors, the EVs derived
from cancer cells induce such CaF-like phenotypes in
cancer surrounding stromal cells (Table 1). Webber et al.
showed that TGF-b was loaded on the surface of EVs
derived from prostate cancer and mesothelioma cell lines
[19, 20]. These cancer-derived EVs could trigger the TGF-
b/SMAD3 signaling pathway in fibroblasts and induce the
myofibroblast-like phenotypes, including the induction of
a-smooth muscle action (a-SMA) expression and the pro-
duction of fibroblasts growth factor 2 (FGF2) [19]. These
data suggest that cancer cells could dictate the characters of
their surrounding stromal cells via EVs and create a con-
venient microenvironment to support cancer cell survival
and progression.
In contrast, stromal fibroblasts that are ‘‘educated’’ by
cancer cells also secreted EVs and established the com-
munication networks that provide the ultimate benefit for
cancer progression. Luga et al. demonstrated that CD81-
positive CaF-derived EVs enhanced breast cancer cell
motility and metastasis by activating the Wnt-planar cell
polarity (PCP) signaling pathway [21]. Endocytosis and
internalization of the Wnt-receptor complex from the
plasma membrane are required for signal transduction [22].
Wnt11 and CD81 are localized on EVs, and the internal-
ization of CD81 molecules on the EVs in breast cancer cell
may support the endocytic trafficking of autocrine Wnt
ligand to activate the Wnt-PCP pathway [21]. Because
CD81 is a well-known marker of EVs [7], it is possible that
CD81-positive EVs derived from other cell types within
the tumor microenvironment may contribute to the acti-
vation of the Wnt-PCP pathway in cancer cells. Boelens
et al. demonstrated that resistance to chemotherapy and
radiation in breast cancer is mediated by CaF-derived EVs
[23]. These CaF-derived EVs contain non-coding or
transposable RNAs that stimulate RIG-I recognition to
activate STAT1. Activated STAT1 cooperates with jux-
tacrine-activated NOTCH3 to mediate NOTCH target gene
transcriptions. NOTCH and its target genes support the
maintainance of tumor-initiating cells that are known to be
resistant to chemotherapy and radiation [24]. Therefore,
NOTCH target gene induction via EVs results in the
expansion of therapy-resistant tumor-initiating cells [23].
Interestingly, CaF-derived EVs preferentially affect breast
cancer cells with the basal-like subtype that is associated
with aggressive phenotype of breast cancer [23, 25].
Although the mechanism by which CaF-derived EVs could
preferentially affect basal-like subtype breast cancer cells
has not been addressed, CaF-derived EVs potentially have
a tropism to influence treatment-resistant cancer cells.
Recently, an increasing number of reports have
demonstrated that secreted miRNAs also enable to com-
pose the communication networks between cancer cells
and CaFs to modulate cancer progression. Pang et al.
showed that miR-155 was secreted through cancer-derived
EVs and dictated CaF-like phenotypes in fibroblasts by
repressing TP53INP1 [26]. This finding suggests that
cancer-derived EVs also affect stromal fibroblasts through
transferring miRNAs. However, Josson et al. demonstrated
that CaF-derived EVs contain miR-409, which promotes
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Fig. 1 Cancer cell-derived EVs modify the characters of cancer
surrounding microenvironment. Several kinds of cell types, such as
cancer cells, fibroblasts, immune cells, endothelial cells, epithelial
cells, and mesenchymal stem cells, comprise unique microenviron-
ment for cancer progression. Cancer cells utilize EVs to modify
surrounding cells within tumor microenvironment. Cancer-derived
EVs have multiple functions that depend on component molecules of
EVs. To induce cancer-associated fibroblast (CaF)-like phenotypes in
cancer surrounding fibroblasts and mesenchymal stem cells, cancer
cells secrete EVs and transfer growth factors and microRNAs
(miRNAs), including transforming growth factor-beta (TGF-b) and
miR-155, respectively. To escape from immune surveillance, cancer
cells transfer several types of immunoregulatory molecules into
immune cells. However, these cancer-derived EVs also stimulate
cancer immunity to kill tumor cells because tumor antigens were
packaged in EVs and stimulated cancer immunity. Cancer-derived
EVs also contain angiogenic proteins and miRNAs that promote
migration and proangiogenic activity of endothelial cells. In addition,
miR-105 and miR-181c in EVs are capable of rupturing the vascular
system to increase the permeability that supports cancer metastasis.
Cancer-derived EVs confer malignant phenotypes in other cancer
cells and epithelial cells by transferring oncogenic proteins and
miRNAs, such as EGFRvIII, miR-200, and tissue transglutaminase
(tTG). Taken together, cancer cells ‘‘dictate’’ the characters of their
surrounding stromal cells and create a convenient microenvironment
to support cancer progression via EVs
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the epithelial-to-mesenchymal transition (EMT) [27].
Moreover, Yeung et al. demonstrated that CaFs and cancer-
associated adipocytes secreted miR-21 via EVs and con-
ferred chemo-resistance to cancer cells by regulating
apoptotic peptidase activating factor 1 (APAF1) expression
[28]. Because miRNA expression changes involve regu-
lating the tumor-promoting function of CaFs [29], the
miRNA expression profile in CaFs and their EVs reflect the
disease status of cancer. Understanding EV communication
networks in tumor-stromal interaction will enable the
development of therapeutic strategies to target EVs and
may provide novel functional marker of CaFs.
Cancer cells can reprogram their energy metabolism to
be distinct from that of normal cells [3, 30]. Interestingly,
Fig. 2 The functional role of non-tumoral cell-derived EVs in cancer
initiation and progression. Non-tumoral cells utilize EVs to affect
cancer initiation and progression. Cancer-associated fibroblasts
secrete EVs and affect invasion, proliferation, chemoresistance, and
metabolic properties of cancer cells by transferring CD81, miR-21,
miR-409, and metabolites. Macrophage-derived EVs contain miR-
223, which stimulates the invasive activity of cancer cells. Monocytes
transfer miR-155 to neuroblastoma via EVs and induce chemoresis-
tance in neuroblastoma. ‘‘Non-educated’’ mesenchymal stem cells
(MSCs) by cancer cells secrete EVs containing miR-16 to suppress
tumor growth and angiogenesis. However, interestingly, ‘‘educated’’
MSCs by cancer cells enable to secrete EVs that contain tumor
promotive proteins such as plakoglobin and CCL2. MSC-derived EVs
also transfer miR-23b, which induce dormant state of cancer cells to
survive in a quiescent state while waiting for the appropriate
environmental conditions to begin proliferation again. Non-aberrant
epithelial cells secreted EVs to transfer miR-143 into cancer cells and
suppress tumor growth
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CaFs within tumor stroma also support the metabolic
properties of cancer cells [31, 32]. Zhao et al. showed that
CaF-derived EVs alter the metabolic properties of prostate
cancer cells [33]. In the presence of CaF-derived EVs,
oxidative phosphorylation is inhibited, but glycolysis and
lactate levels are increased in prostate cancer cell lines.
This finding suggests that EVs induce the ‘‘Warburg
effect’’ [30, 34]. These CaF-derived EVs also transfer TCA
cycle metabolites, amino acids, and lipids into cancer cells.
Interestingly, breast cancer-derived EVs also modify the
glucose consumption of fibroblasts in metastatic sites by
targeting pyruvate kinases [35]. Therefore, cancer-derived
EVs enable to educate stromal cells within distant niche to
promote cancer metastasis. Similarly, several reports also
showed the important aspects of cancer-derived EV on the
cancer progression through remodeling the stromal cells
within pre-metastatic niche [36, 37]. Although further
studies are required to clarify the advantages of metabolic
change in cancer progression, these findings suggest that
the communication networks of EVs contribute to cancer
proliferation and survival in the surrounding environment
with limited oxygen and nutrient supplies.
Cancer-derived EVs in the immune system
The major function of the immune system is not only to
protect against several infectious pathogens but also to
eradicate the abnormal cells [40]. Therefore, to promote
cancer initiation and progression, evasion from immune
surveillance is one of the key hallmarks of cancer cells [3].
However, increasing evidences indicate that the immune
systems play a dual role in cancer progression and can both
suppress and support the tumor cells. In addition, several
reports suggested that macrophages and neutrophils within
tumor tissue were associated with cancer progression
[40–44]. These macrophages and neutrophils also exhibit
polarity on either a tumor-suppressive or a tumor-promot-
ing phenotype, depending on the surrounding
microenvironment [43, 44]. Hence, cancer cells and
immune cells form intricate communication networks that
affect the risk of cancer development.
EVs also modulate the evasion of cancer cells from
immune surveillance (Table 2). For example, cancer-
derived EVs induce apoptosis of CD8-positive T-cells and
promote regulatory T-cell expansion to suppress anticancer
immunity [45, 46]. Additionally, cancer-derived EVs
included several types of immunoregulatory molecules,
such as FasL [47], TGF-b [48], NKG2D ligands [49],
galectin-9 [50], and HSP72 [51], to support the immune
escape of cancer cells. These EVs also induce the differ-
entiation of monocytes into immunosuppressive
macrophages [52]. Interestingly, cancer-derived EVs
increase the survival rate of monocytes [53, 54]. Conse-
quently, cancer-derived EVs facilitate the formation of
macrophages from monocytes in the tumor microenviron-
ment. These macrophages are also capable of producing the
EVs that enhance the metastatic properties of cancer cells
Table 1 EV interaction between cancer cells and fibroblasts
Cell types of EV
donor
Cell types of EV
recipient
EV components Functions References
Positive regulation of extracellular vesicles on cancer progression
Cancer cells Fibroblasts TGF-b Triger the myofibroblast differentiation [19]
TGF-b Triger the myofibroblast differentiation and promote cancer
growth and angiogenesis
[20]
Integrins Up-regulates S100 gene expressions and promote cell
growth and migration
[38]
miR-155 Induce cancer-associated fibroblast-like phenotype through
repressing TP53P1
[26]
miR-122 Down-regulates glucose consumption of fibroblasts [35]
Fibroblasts Cancer cells CD81 Enhance cancer motility and metastasis [21]
Extracellular matrix proteins
and ADAM10
Promote cancer motility [16]
Non-coding of transposable
RNAs
Expansion of therapy-resistant tumor-initiating cells [23]
miR-409 Promote epithelial-mesenchymal transition [27]
Wnt3a Expansion of cancer stem cell to enhance chemoresistance [39]
miR-21 isomiR Confer the chemo-resistance through targeting APAF1 [28]
Metabolites including amino
acids and lipids
Affect of metabolic properties of cancer cells [33]
How cancer cells dictate their microenvironment: present roles of extracellular vesicles 701
123







EV components Functions References





FasL Induce the apoptosis of lymphocytes [47]
FasL and HLA class I antigens Induce apoptosis and caspase activation [71]
FasL and TRAIL Induce T-cell apoptosis [72]
Several proteins including chemokine receptor 6 (CCR6)
and CD44 variant 7/8
Increase the survival rate of monocytes [53]
CD44 Induce tumor-associated macrophage-like
phenotypes from monocytes
[73]
TGF-b Inhibit NK cell cytotoxic function and enhance
regulatory T cell immune suppressive
function
[48]
NKG2D and TGF-b Inhibit lymphocyte effector function [49]
Melanoma antigen (MAGE), FasL and MHC class I Apoptosis of CD8 positive T-cell and promote
regulatory T cell expansion
[45]
Galectin-9 Induce the apoptosis of mature Th1 lymphocytes [50]
IL-10, TGF-b, FasL, MAGE and MHC class I Apoptosis of CD8 positive T-cell and promote
regulatory T cell expansion
[46]
HSP72 Induce immunosuppressive activity of myeloid-
derived suppressor cells
[51]
Palmitoylated proteins Induce pro-inflammatory cytokines, including
IL-6, TNF-a and CCL2, through activating
NF-jB signaling
[56]
Chondroitin sulfate proteo-glycan 4, a2-macroglobulin,
lactadherin, syntenin-1, myristoylated alanine-rich
C-kinase substrate (MARCKS), integrin alpha-V,
integrin alpha-3, and epithelial growth factor receptor
(EGFR)
Induce the differentiation of monocyte into
immunosuppressive macrophages
[52]
Phospholylated receptor thyrosin keinase Increase the survival rate of monocytes by
regulating the MAPK pathway
[54]
miR-203 Suppress the expression of the immune
response-relative genes, and may contribute
to suppressing anticancer immunity
[65]








Migration inhibitory factor (MIF) Promote TGF-b secretion in Kupffer cells and







miR-223 Stimulates the invasive activity of breast cancer
cells by regulating the Mef2c-b-catenin
pathway
[55]
miR-155 Enhance chemoresistance of cancer cells
through targeting TERF1
[66]
miR-126a Induce IL-13 positive Th2 macrophage
maturation and promote tumor angiogenesis
that lead to cancer cell metastasis
[74]





Melanoma antigen (Mart1) Stimulated cancer immunity to kill tumor cells [57]
Tumor antigens Stimulated cancer immunity to kill tumor cells [58]
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[55]. Moreover, cancer-derived EVs internalize into mac-
rophages and induce pro-inflammatory cytokines,
including IL-6, TNF-a, and CCL2, through activating NF-
jB signaling [56]. Thus, EV communications between
cancer cells and immune cells seem to provide the
advantage of evasion from immune surveillance and cancer
progression. However, several researchers suggested that
tumor antigens were packaged in EVs and stimulated
cancer immunity to kill tumor cells [57, 58]. Therefore,
cancer-derived EVs are also utilized as anti-tumoral vac-
cines [59, 60]. In addition, dendritic cells (DC)-derived
EVs induce CD8-positive T-cell activation in both a CD4-
positive T-cell and B-cell-dependent manner [61]. The
availability of these DC-derived EVs as a tool of vaccine
immunotherapy was also tested [62–64]. Taken together,
EVs within the tumor microenvironment also participate in
such complex interactions between cancer cells and
immune cells.
Among these communication networks of the EVs
involved in cancer immunity, the miRNAs secreted via
EVs are also involved in the regulation of cancer immunity
(Fig. 1; Table 2). Indeed, pancreatic cancer-derived EVs
containing miR-203 regulate the expression of the immune
response-relative genes, including toll-like recepter-4, and
may contribute to suppress anticancer immunity [65]. In
addition, macrophage-derived EVs can transfer miR-223,
which stimulates the invasive activity of breast cancer
cells, by regulating the Mef2c-b-catenin pathway [55].
Furthermore, miR-21 is transferred into monocytes via
neuroblastoma-derived EVs and can bind to TLR8 to
stimulate NF-jB pathway and induce miR-155 expression
in monocytes [66]. Interestingly, miR-155 is also trans-
ferred from monocytes to neuroblastoma via EVs and
induces chemoresistance in neuroblastoma through target-
ing telomeric repeat binding factor 1 (TERF1). Such
communication networks of secreted miRNAs via EVs are
likely associated with programmed cell death protein
ligand-1 (PD-L1) in mediating the immune response. PD-
L1 is well known as a ligand of programmed cell death
protein-1 (PD-1) that plays a pivotal role in T-cell
inhibition and exhaustion. PD-L1 is up-regulated in several
cancers to suppress the cytotoxic activity of T-cells and
escape from the immune system. Instability of the PD-L1
30-untranslated region (UTR) was recently reported to be
associated with aberrant PD-L1 expression in cancer cells
[67]. Importantly, most miRNA targeting sites are located
in the 30-UTR region of target genes [68]. Several reports
have demonstrated the functional role of miRNAs in
immune checkpoints by regulating PD-L1 expression
[69, 70]. Although it is unclear that miRNAs targeting PD-
L1 are packaged in EVs, it is conceivable that the genetic
status of PD-L1 may affect the functional role of the
secreted miRNAs that are included in EVs in the evasion of
cancer cells from immune surveillance. Further under-
standing of the molecular mechanisms underlying these
complex communication networks via EVs will provide
several avenues for cancer immunotherapy and diagnosis.
The communication network of EVs
between cancer cells and endothelial cells
Angiogenesis within tumor tissue is required to provide
nutrients and oxygen to cancer cells and allows entry to the
blood circulation system [3, 77, 78]. Angiogenesis can
trigger the formation of metastatic foci in secondary sites.
Tumor vascularization is regulated by a number of poten-
tial mechanisms, and vascular endothelial cells are one of
the origins of the tumor vessel [79]. Cancer-derived EVs
support the vascularization by affecting endothelial cells
within the tumor microenvironment and may confer the
aggressive phenotypes to cancer cells (Table 3). For
instance, prostate and ovarian cancer cells secrete EVs to
transfer sphingomyelin and CD147 into endothelial cells.
These EV molecules promote migration and proangiogenic
activity of endothelial cells [80, 81]. Similarly, nasopha-
ryngeal cancer-derived EVs contained intercellular
adhesion molecule-1 (ICAM-1) and CD44 variant isoform
5 (CD44v5), which significantly increase the migration,













Tumor peptide, MHC class I and II Stimulated cancer immunity to kill tumor cells [75]
Cytosolic proteins (including hsc73) and membrane
proteins (including milk fat globule-EGF-factor VIII
(MFG-E8))
Stimulated cancer immunity [76]
MHC class I Induce CD8-positive T-cell activation in both a
CD4-positive T-cell and B-cell dependent
manner
[61]
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Although these reports did not clarify the contribution of
these EV components in cancer progression, cancer-
derived EV-induced angiogenesis within the tumor
microenvironment probably supports cancer survival and
metastasis.
In contrast, cancer cell-derived EVs also transported
miRNAs into endothelial cells to modulate neovascular-
ization. Metastatic breast cancer-derived EVs transport
miR-210 into endothelial cells [83]. This miRNA secretion
is regulated by neutral sphingomyelinase 2 (nSMase2),
which is highly expressed in cancer cells compared with
non-neoplastic cells [83–85]. Because nSMase2 expression
promotes metastatic initiation, miRNA secretion via can-
cer-derived EVs modulates cancer metastasis through neo-
vascularization. The functional role of EVs containing
miR-135 and miR-210 in tumor angiogenesis is also
observed in multiple myeloma and leukemia, respectively
[86, 87]. Interestingly, hypoxic conditions promote the
secretion of EVs containing miR-135 and miR-210 in
cancer cells [86, 87]. Hypoxic conditions within tumor
tissues affect several characteristics of cancer, including
angiogenesis [88]. Furthermore, hypoxia promotes EV
release and alteration in the EV components [89, 90].
Therefore, EVs are utilized to facilitate the malignant
behavior in hypoxic tumor microenvironments. However,
the exact contribution of miRNAs and proteins in EVs
during angiogenesis and cancer metastasis remains unclear.
Understanding these relationships will enable the devel-
opment of cancer therapy. Indeed, anti-angiogenic
strategies to inhibit EVs secretion and miRNA contents
were examined [91].
Cancer-derived EVs mediate tumor angiogenesis within
proximal microenvironments. However, cancer cells also
utilize EVs for endothelial cell modifications within distant
microenvironments to form a metastatic niche. For
instance, the blood–brain barrier (BBB) tightly regulates
the permeability from the vascular system to the central
nervous system [88, 92, 93]. Thus, BBB destruction is one
of the key steps to allow the extravasation of cancer cells
during brain metastasis [88]. Although several types of
molecules contributed to the BBB disruption [92, 94], EVs
are also associated with brain metastasis of cancer cells by
affecting BBB endothelial cells. A recent study indicated
that brain metastasis breast cancer-derived EVs containing
miR-181c were closely associated with the BBB destruc-
tion and brain metastasis [95]. miR-181c is transferred into
endothelial cells of the BBB by EVs and causes the delo-
calization of actin by suppressing the expression of
3-phosphoinoitide-dependent protein kinase-1 (PDPK1).
PDPK1 suppression leads to the degradation of the





EV components Functions References





Sphingomyelin Promote migration and vascularization of
endothelial cells
[80]
Tetraspanin CO-029/D6.1A (as known
tetraspanin-8 (TSPAN-8)
Induce vascularization [98]
CD147 Promote migration and vascularization of
endothelial cells
[81]
Several molecules including TSPAN-8, CD49d
and CD106
Enhance cell growth, migration, vascularization
and maturation of endothelial cells
[99]
IL-6, VEGF, MMP2 Induce vascularization of endothelial cells [100]
Intercellular adhesion molecule-1 (ICAM-1) and
CD44 variant isoform 5 (CD44v5)
Promote migration and vascularization of
endothelial cells
[82]
H19 long non-coding RNA Promote an angiogeneic phenotype in
endothelial cells
[101]
miR-9 Promote migration and vascularization of
endothelial cells
[102]
miR-210 Modulates cancer metastasis through
neovascularization
[83]
miR-210 Induce vascularization of endothelial cells [87]
miR-135 Induce vascularization of endothelial cells [86]
miR-105 Destroy the tight junction of the endothelial cells
to promote metastasis
[96]
miR-181c Disrupt the permeability of the BBB to promote
brain metastasis
[95]
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phosphorylated cofilin, which is important for actin
dynamics and disrupts the permeability of the BBB. Sim-
ilar to this report, Zhou et al. reported that metastatic breast
cancer-derived EVs also contain miR-105 that directly
inhibits tight junction protein 1 (ZO-1) expression in
endothelial cells and destroys the tight junction to promote
metastasis [96]. It appears that miR-181c is included in the
EVs that preferentially accumulate in brain endothelial
cells, but EVs that contain miR-105 may affect endothelial
cells throughout the body. Therefore, cancer-derived EVs
may participate in such organ-specific metastasis of cancer
cells through remodeling the distal pro-metastatic niche.
Indeed, pancreatic cancer-derived EVs are selectively
uptaken by liver Kupffer cells and promote liver metastasis
of cancer cells [97]. In addition, cancer-derived EVs had a
tropism depending on surface integrin marks [38]. How-
ever, it is still controversial whether all of cancer-derived
EVs exhibit specificity for the pre-metastatic niche.
Clarification of these points is necessary for the use of EVs
as novel therapeutic targets of cancer metastasis.
The functional role of EVs on intercellular
communication between cancer cells
and mesenchymal stem cells
Cancer-derived EVs affect the mesenchymal stem cells
(MSCs) as well as fibroblasts and endothelial cells
(Table 4). MSCs reside in several types of mesodermal
tissues, such as bone marrow (BM), adipose tissue,
umbilical cord, and peripheral blood [103–105]. Several
lines of evidence indicated that these MSCs are recruited
into the tumor microenvironment and could promote tumor
growth and metastasis [106, 107]. Cancer-derived EVs
control the differentiation of BM-MSCs to a CaF-like state
through activating the TGF-b signaling pathway [108].





EV components Functions References
Positive regulation of extracellular vesicles on cancer progression
Cancer cells Mesenchymal
stem cells
TGF-b Induce cancer-associated fibroblast-like
phenotype through activating TGF-b/
SMAD pathway
[119]
TGF-b Induce cancer-associated fibroblast-like
phenotype and enhance tumor proliferation
and invasion
[108]
Functional miRNA and proteins Induce cancer-associated fibroblast-like
phenotype and enhance tumor proliferation
[109]
miR-146a Induction of several cytokines and
chemokines in mesenchymal stem cells, and
enhance cancer viability and migration
[120]
Cancer cells Bone marrow
progenitor
cells
MET Change the phenotype and mobilzation of





Cancer cells Fibronectin, Junction plakoglobin, and CCL2
from cancer ‘‘educated’’ mesenchymal stem
cells
Promote cancer proliferation and
dissamination
[118]
Probably transferred HGF mRNA by EVs Promte cancer growth and migration [116]
miR-23b Induce cancer cell dormancy [113]
miR-21, miR-34a, PDGFR-b, TIMP-1, TIMP-2,
lactic acid, glutamic acid, and sphingomyelin
Increase cancer cell proliferation and survival [122]
Bone marrow
stromal cells
Cancer cells monocyte chemo- attractant protein 1 (MCP-1),
interferon-inducible protein 10 (IP-10),
stromal cell-derived factor 1 (SDF-1)
Promote cancer cell growth, migration, and
drug resistance
[123]
Negative regulation of extracellular vesicles on cancer progression
Mesenchymal
stem cells
Cancer cells miR-16 Inhibit tumor vascularization through
suppressing VEGF expression
[115]
miR-15 from healthy donor-derived
mesenchymal stem cells
Inhibit cancer proliferation and dissamination [118]
Bone marrow
stromal cells
Cancer cells miR-146b Inhibit cancer growth [124]
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This differentiated BM-MSC with EVs exhibits proangio-
genic properties to enhance tumor proliferation and
invasion. Similarly, Paggetti et al. demonstrated that
chronic lymphocytic leukemia (CLL) cells also secreted
EVs to induce CaF-like phenotypes in BM-MSCs and
endothelial cells [109]. BM-MSCs and endothelial cells
with CLL-derived EVs support CLL adhesion, survival,
and growth in vitro and in vivo. The origins of CaFs are
still controversial, and cancer-derived EVs also induce
CaF-like phenotypes in cancer surrounding fibroblasts [14].
Therefore, cancer-derived EVs can convert several types of
stromal cells into CaF-like cells. These data suggest that
EVs are associated with CaF population diversity.
Breast cancer patients have a protracted risk of recur-
rence within 5 years and even up to 10–20 years after
surgery or adjuvant chemotherapy [110–112]. The phe-
nomenon indicates that breast cancer cells acquire a
dormant state and survive for a long time in the patient’s
body. Although cancer cells cease dividing under a dor-
mant state, they can survive in a quiescent state while
waiting for the appropriate environmental conditions to
begin proliferation again. Importantly, BM-MSCs con-
tribute to the maintenance of such cancer cell dormancy via
EVs [113]. BM-MSCs transfer miR-23b-containing EVs
into breast cancer cells and modulate the dormant state by
targeting myristoylated alanine-rich C-kinase substrate
(MARCKS), which modulates cell motility and cell cycle
progression [114]. Consistent with this report, it was also
indicated that BM-MSCs secreted miR-16 via EVs and
downregulated vascular endothelial growth factor (VEGF)
expression to lead to the inhibition of growth and
angiogenesis in breast cancer [115]. In contrast, several
reports also showed that these MSC-derived EVs promoted
tumor growth in renal cancer [116], gastric cancer, and
colorectal cancer [117]. Thus, the functional role of MSC-
derived EVs depends on cancer cell types. In addition, it
was reported that EVs derived from BM-MSCs of multiple
myeloma patients enhance tumor growth but that healthy
subject-derived BM-MSCs suppress tumor growth via EVs
[118]. Taken together, these different functions of MSC-
derived EVs depending on the phenotypes of cancer cells.
Understanding these points will provide a novel insight
into cancer therapy.
Horizontal propagation of oncogenic molecules
by EVs
As mentioned above, cancer-derived EVs controlled stro-
mal cells within the tumor microenvironment to promote
cancer progression. However, cancer cells can also transfer
their oncogenic properties to other cancer cells via EVs
(Table 5). For instance, the epithelial growth factor
receptor (EGFR) truncated mutant, EGFR variant III
(EGFRvIII), is closely associated with cancer progression
and poor patient prognosis of glioblastoma (GBM), which
is most common brain malignancy in adults [125]. Al-
Nedwi et al. reported that the EGFRvIII could be trans-
ferred from EGFRvIII-positive GBM cells to negative
GBM cells through EVs [126]. Internalization of EGFR-
vIII-containing EVs activated the MAPK and Akt signaling
pathways in the EGFRvIII-negative GBM cells, resulting
Table 5 EV interaction between cancer cells and another cancer cells
Cell types of
EV donor
Cell types of EV
recipient
EV components Functions References
Positive regulation of extracellular vesicles on cancer progression
Cancer cells Cancer cells H-ras and c-myc Induce tumorigenic phenotypes [12]
EGFR variant III (EGFRvIII) Induce both morphological changes and anchorage-
independent growth
[126]
EGFRvIII mRNA Stimulate cancer cell proliferation [127]
Integrin Promote adhesion and migration [132]
miR-200 family Induce the mesenchymal to epithelial transition
(MET) to promote metastasis
[130]
Several miRNAs including miR-584 Activate JNK/p38 MAPK pathway and promote
tumor growth
[133]
miR-10b Promte invasion activity [134]
Several miRNAs including miR-100,
miR-222, and miR-30a
Increase survival rate [135]
miR-222 Promote invesion and motility [136]
Long non-coding RNA (lncARSR) Stimulate AXL and c-MET expression to enhance
chemoresistance
[131]
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in the expression of EGFR target genes, including vascular
endothelial growth factor (VEGF). Furthermore, EGFR-
vIII-containing EVs induce both morphological changes
and anchorage-independent growth in recipient cells.
Interestingly, EGFRvIII mRNA is also detectable in GBM-
derived EVs [127]. Given that some reports demonstrated
the heterogeneous distribution of EGFRvIII expression in
GBM tissue [128, 129], the horizontal propagation of
EGFRvIII by EVs might contribute to intratumoral
heterogeneity and the progression of GBM. Such intracel-
lular interactions by EVs between malignant tumor cells
and less aggressive tumor cells were also observed in other
types of cancer. Le et al. showed that highly metastatic
breast cancer cells could transfer the EVs contained miR-
200 family miRNAs to non-metastatic breast cancer cells
to promote lung metastasis [130]. This miR-200 transfer
induces the mesenchymal to epithelial transition (MET) by
altering the expression of genes, including zeb2 and
sec23a, in non-metastatic breast cancer cell lines. Qu et al.
demonstrated that long non-coding RNAs (lncRNAs) were
also transferred by EVs and contributed to the chemore-
sistance of renal cell carcinoma (RCC) cells [131]. This
lncRNA, termed lncARSR, acts as a competitor of miR-34/
miR-449 and stimulates AXL and c-MET expression to
enhance chemoresistance in drug-sensitive RCC cells.
From these reports, cancer-derived EVs play a crucial role
in the acquisition and transfer of the malignant trait by
horizontal propagation of oncogenic molecules.
Interaction between non-tumoral epithelial cells
and cancer cells via EVs
Competitive cell interactions represent a basic biological
process to maintain homeostasis [137]. In particular, during
cancer initiation, aberrant cells bearing genetic or epige-
netic mutations will conflict with the surrounding non-
aberrant normal cells to eliminate them from the cell
population [137, 138]. If these aberrant cells eliminate
normal cells from tissue, it may lead to cancer formation
and progression. Therefore, it is conceivable that normal
cells require an eradication system for aberrant cells to
prevent tumor initiation. Normal prostate epithelial cell
lines secreted EVs to transfer the tumor suppressor miR-
143 into cancer cells [85] (Table 6), resulting in the
induction of growth inhibitory signals in prostate cancer
cells. These results suggest that EVs may contribute to the
maintenance of normal growth and prevent cancer initia-
tion. In contrast, cancer cells also utilize EVs to overcome
this cell competition with non-tumoral epithelial cells
during the cancer initiation step. Breast cancer-derived EVs
are capable of inducing anchorage-independent growth and
survival in mammary epithelial cells [139] (Table 6).
Similar to this report, high metastatic hepatocellular car-
cinoma cell lines also transfer the oncogenic molecules to
the non-tumoral immortalized hepatocytes and promote
invasive activity of the immortalized hepatocytes [140].
Therefore, cancer-derived EVs contribute to the expansion
of cancer cells by transforming non-aberrant normal cells.
From these reports, it is conceivable that EVs play an
important role in cell competition between cancer cells and
non-tumoral epithelial cells. Further investigation will
advance our understanding of the progression mechanisms
of competitive cellular interaction between cancer cells and
epithelial cells.
Conclusion
The precise mechanisms of intercellular communication in
the tumor microenvironment remain obscure because there
are many important pathways that modulate multiple non-
EV factors, such as growth factors, cytokines, and che-
mokines. However, as described above, the rapid
development of EV research elucidated the novel mecha-
nism underlying the intrinsic intercellular communication
networks during cancer initiation and progression. EVs
possess impressively diverse functions in the intercellular
communication networks in the tumor microenvironment.
Cancer cells secrete EVs and dictate the phenotypes of
surrounding cells to promote cancer progression. Against
such ‘‘education,’’ non-tumoral cells utilized EVs to sup-
press cancer initiation and progression. Understanding the
precise mechanisms of EVs in cancer biology may provide
a breakthrough in the diagnostic and prognostic tools and
therapeutic strategies of cancer.
Table 6 EV interaction between cancer cells and epithelial cells
Cell types of EV
donor
Cell types of EV
recipient
EV components Functions References
Positive regulation of extracellular vesicles on cancer progression
Cancer cells Epithelial cells Tissue transglutaminase
(tTG)
Induce anchorage-independent growth and
survival
[139]
Epithelial cells Cancer cells miR-143 Induce growth inhibitory signals [85]
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